PMID- 35438460
OWN - NLM
STAT- MEDLINE
DCOM- 20220929
LR  - 20220929
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 116
IP  - 4
DP  - 2022 Oct
TI  - Successful HLA-haploidentical stem cell transplantation with post-transplant 
      cyclophosphamide in an older patient with chronic active Epstein-Barr virus 
      infection.
PG  - 630-634
LID - 10.1007/s12185-022-03345-5 [doi]
AB  - Chronic active Epstein-Barr virus infection (CAEBV) is a subtype of 
      EBV-associated T/NK cell lymphoproliferative disease and is only curable by 
      allogeneic hematopoietic stem cell transplantation. However, finding a human 
      leukocyte antigen (HLA)-matched donor at a suitable time can sometimes be 
      difficult. We report the case of a 60-year-old woman who received prednisolone 
      (PSL) after being diagnosed with autoimmune hepatitis 3 years earlier. She 
      suddenly developed high fever and impaired liver function. Based on a high EBV 
      DNA load in the peripheral blood, CAEBV was diagnosed. The patient was started on 
      cooling therapy with PSL, cyclosporine, and etoposide, which reduced symptoms. 
      Subsequently, she received HLA-haploidentical stem cell transplantation 
      (haplo-SCT) with reduced-intensity conditioning (fludarabine 25 mg/m(2) for 
      5 days, melphalan 50 mg/m(2) for 2 days, and total body irradiation at 2 Gy) and 
      post-transplant cyclophosphamide (PTCy) because she lacked an HLA-matched donor. 
      Liver function was restored, and EBV DNA load in peripheral white blood cells 
      became undetectable. The patient is alive without relapse or severe complications 
      over 1 year after transplantation. To our knowledge, this is the first report of 
      successful haplo-SCT with PTCy for CAEBV. This approach may be an alternative 
      therapeutic option for CAEBV patients lacking an HLA-matched donor.
CI  - (c) 2022. Japanese Society of Hematology.
FAU - Maegaki, Masaya
AU  - Maegaki M
AD  - Department of Hematology, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 
      Tottori, 683-8504, Japan.
FAU - Kawamura, Koji
AU  - Kawamura K
AD  - Department of Hematology, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 
      Tottori, 683-8504, Japan.
AD  - Division of Clinical Laboratory Medicine, Department of Multidisciplinary 
      Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.
FAU - Hara, Kentaro
AU  - Hara K
AD  - Department of Hematology, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 
      Tottori, 683-8504, Japan.
FAU - Hosoda, Rina
AU  - Hosoda R
AD  - Department of Hematology, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 
      Tottori, 683-8504, Japan.
FAU - Suzuki, Sayaka
AU  - Suzuki S
AD  - Department of Hematology, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 
      Tottori, 683-8504, Japan.
AD  - Division of Clinical Laboratory Medicine, Department of Multidisciplinary 
      Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.
FAU - Hosoda, Yuzuru
AU  - Hosoda Y
AD  - Department of Hematology, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 
      Tottori, 683-8504, Japan.
AD  - Division of Clinical Laboratory Medicine, Department of Multidisciplinary 
      Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.
FAU - Imadome, Ken-Ichi
AU  - Imadome KI
AD  - Department of Advanced Medicine for Infections, National Center for Child Health 
      and Development (NCCHD), Tokyo, Japan.
FAU - Motokura, Toru
AU  - Motokura T
AD  - Division of Clinical Laboratory Medicine, Department of Multidisciplinary 
      Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.
FAU - Fukuda, Tetsuya
AU  - Fukuda T
AUID- ORCID: 0000-0002-4632-8429
AD  - Department of Hematology, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 
      Tottori, 683-8504, Japan. tfukuda@tottori-u.ac.jp.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220418
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Cyclosporins)
RN  - 0 (HLA Antigens)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Cyclophosphamide/therapeutic use
MH  - *Cyclosporins/therapeutic use
MH  - *Epstein-Barr Virus Infections/complications
MH  - Etoposide/therapeutic use
MH  - Female
MH  - *Graft vs Host Disease/etiology
MH  - HLA Antigens
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Herpesvirus 4, Human
MH  - Humans
MH  - Melphalan/therapeutic use
MH  - Middle Aged
MH  - Prednisolone/therapeutic use
MH  - Transplantation Conditioning/adverse effects
OTO - NOTNLM
OT  - Chronic active Epstein-Barr virus infection (CAEBV)
OT  - HLA-haploidentical stem cell transplantation (haplo-SCT)
OT  - Post-transplant cyclophosphamide (PTCy)
EDAT- 2022/04/20 06:00
MHDA- 2022/09/30 06:00
CRDT- 2022/04/19 12:10
PHST- 2021/12/19 00:00 [received]
PHST- 2022/03/31 00:00 [accepted]
PHST- 2022/03/31 00:00 [revised]
PHST- 2022/04/20 06:00 [pubmed]
PHST- 2022/09/30 06:00 [medline]
PHST- 2022/04/19 12:10 [entrez]
AID - 10.1007/s12185-022-03345-5 [pii]
AID - 10.1007/s12185-022-03345-5 [doi]
PST - ppublish
SO  - Int J Hematol. 2022 Oct;116(4):630-634. doi: 10.1007/s12185-022-03345-5. Epub 
      2022 Apr 18.